Search Results - "V. V. Ptushkin"

Treatment of bone complications in multiple myeloma patients by V. V. Ptushkin

“…Multiple myeloma frequently leads to bone complications characterized by the presence of lytic defects with high incidence of pathologic fractures,…”
Get full text

Impact of low-molecular-weight heparins on survival of cancer patients by V. V. Ptushkin

Get full text

Controversial issues in the management of anemia with erythropoietins in cancer patients by V. V. Ptushkin

Get full text

Missions and potentialities of municipal oncohematological service by V V Ptushkin

“…Hematology, especially oncohematology is one of the most science-intensive medical fields, with increasing precision of diagnostics and efficacy of treatment…”
Get full text

PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS by V. V. PTUSHKIN

“…Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Cancer-associated thrombosis is a major cause of morbidity and…”
Get full text

Analysis of the effectiveness of multiple myeloma treatment based on the clinical experience of European countries by Ptushkin, Vadim V., Mueller, Mario

“…Aim. The main aim of this study was to model the effectiveness of multiple myeloma (MM) therapy using machine learning, which was based on the analysis of…”
Get full text

Prognostic factors of the efficiency of obtaining the autologous precursor cells of hemopoiesis for further transplantation after large-dose chemotherapy: review of literature and the authors' data by A. Yu. Popov, N. N. Zhukov, S. V. Minenko, L. Yu. Andreyeva, V. V. Ptushkin

“…To obtain a sufficient number of hemopoietic progenitor cells (HPCs) for a rapid and stable recovery of hematopoiesis is one of the major conditions for safe…”
Get full text

Role of high-dose chemotherapy with hemopoietic stem cell transplantation in the treatment of multiple myeloma by S. V. Minenko, A. Yu. Popov, N. V. Zhukov, O. M. Votyakova, V. V. Ptushkin

“…Treatment results in a group of patients with multiple myeloma (n=18) treated with melfalan (200 mg/m2) followed by autologous peripheral blood stem cell…”
Get full text

Osteodestruction markers and quality of life parameters at pomegara (pamidronate) treatment in multiple myeloma patients with lytic bone lesions by V. V. Lunin, Ye. V. Yurova, O. A. Kudryavtseva, S. V. Minenko, V. V. Ptushkin

“…The aim of the given study is investigation of influence onosteodestruction markers and quality of life parameters of therapy with generic preparation of…”
Get full text

Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study by Vinogradova, O. Yu, Pankraskina, M. M., Neverova, A. L., Shikhbabaeva, D. I., Murzabekova, M. A., Chernikov, M. V., Popova, A. V., Kosenkova, V. P., Egoryan, L. B., Ptushkin, V. V.

“…Background . Currently, targeted therapy is the most promising for the treatment of myelofibrosis (MF). Today, the results of many years of experience with the…”
Get full text

Role of biosimilars in neutropenia prevention in cancer patients by V. V. Ptushkin

“…Decreasing the neutrophils count in peripheral blood after intensive chemotherapy (CT) dramatically increases the risk of infectious complications.As a…”
Get full text

Role of biosimilars in neutropenia prevention in cancer patients by V. V. Ptushkin

“…Decreasing the neutrophils count in peripheral blood after intensive chemotherapy (CT) dramatically increases the risk of infectious complications.As a…”
Get full text

Targeted therapy for advanced forms of systemic mastocytosis in real clinical practice by Shikhbabaeva, D. I., Vinogradova, O. Yu, Neverova, A. L., Pankrashkina, M. M., Chernikov, M. V., Detkina, E. O., Kobzev, Yu. N., Malakho, S. G., Ptushkin, V. V.

“…Background. Mastocytosis is a heterogeneous group of diseases that are characterized by excessive proliferation and accumulation of clonal (neoplastic) mast…”
Get full text

Role of high-dose chemotherapy with hemopoietic stem cell transplantation in patients with non-Hodgkin's lymphomas by V. V. Ptushkin, N. V. Zhukov, S. V. Minenko, A. Y. Popov, D. M. Mheidze, L. Y. Andreeva

“…High-dose chemotherapy (HDC) with autologous or allogenic hemopoietic stem cell transplantation (SCT) is successfully used in refractory, relapsed or high-risk…”
Get full text

Resolution of the Expert council “Unsolved problems of targeted therapy for paroxysmal nocturnal hemoglobinuria in Russia” by Kulagin, A. D., Lukina, E. A., Ptushkin, V. V., Kostinov, M. P., Arshanskaya, E. G., Babaeva, T. N., Ksenzova, T. I., Fidarova, Z. T., Marchenko, M. V.

“…   On June 24, 2023, an Expert Council was held in St. Petersburg, during which leading experts in the field of hematology discussed current achievements and…”
Get full text

Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia by Komissarov, Alexey A, Kislova, Maria, Molodtsov, Ivan A, Petrenko, Andrei A, Dmitrieva, Elena, Okuneva, Maria, Peshkova, Iuliia O, Shakirova, Naina T, Potashnikova, Daria M, Tvorogova, Anna V, Ptushkin, Vadim V, Efimov, Grigory A, Nikitin, Eugene A, Vasilieva, Elena

“…The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high…”
Get full text

Influence of low molecular weight heparin on cancer patients’ survival by V. V. Ptushkin

“…There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and…”
Get full text

Modern concepts of biosimilars in hematology and oncology by V. V. Ptushkin

“…Biologics are large protein or polypeptide molecules produced by living organisms, which largely determine the efficiency of modern anticancer therapy…”
Get full text

Influence of low molecular weight heparin on cancer patients’ survival by V. V. Ptushkin

“…There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and…”
Get full text

Modern concepts of biosimilars in hematology and oncology by V. V. Ptushkin

“…Biologics are large protein or polypeptide molecules produced by living organisms, which largely determine the efficiency of modern anticancertherapy…”
Get full text